Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

LOS ANGELES, CA / ACCESSWIRE / September 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bausch Health Companies Inc. ("Bausch" or "the Company") (NYSE:BHC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2020 and May 3, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Bausch Health Companies Inc. with Losses of $100,000 to Contact the Firm

Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Bausch (BHC): Can Its 8.0% Jump Turn into More Strength?

Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum Disease Collaboration Launches During Hispanic Heritage Month With Activations Featuring Patient Ambassador Alex Rodriguez LAVAL, QC / ACCESSWIRE / September 21, 2023 / In honor of Hispanic Heritage Month, Bausch Health Companies Inc. (NYSE:BHC),(TSX:BHC) and its oral health care business, OraPharma, today announced its collaboration with the League of United Latin American Citizens (LULAC) - the largest and oldest Hispanic organization in the United States - to foster a greater understanding of gum disease detection, and treatment within the Hispanic community. Gum disease, also known as periodontal disease, is a chronic bacterial infection that affects nearly 65 million American adults and is even more common among Latinos.

League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease

NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Bausch Health Companies Inc. ("Bausch" or the "Company") (NYSE: BHC) of a class action securities lawsuit.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Bausch Health Companies Inc.(BHC) Investors of a Class Action Lawsuit and Upcoming Deadline

Bausch Health stock fell on Tuesday on the news of its CFO unexpectedly leaving. Wednesday brought a bounce as investors viewed the sell-off as a buying opportunity.

Why Bausch Health Stock Is Jumping Today

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue Eye Care Recycling programs have been recognized as 2023 Sustainability Award winners by Business Intelligence Group in the “Sustainability Service of the Year” category. “Millions of people wear contact lenses and use eye care materials every day, but many don't realize the environmen.

Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners

Tom Vadaketh is leaving as Bausch's CFO after less than two years with the company. Vadaketh helped oversee financial improvement for Bausch.

Why Shares of Bausch Health Companies Fell Tuesday

Bausch Health Cos. Inc. BHC, -1.76% shares fell nearly 3% premarket on Tuesday after the company announced late Monday that chief financial officer Tom Vadaketh has resigned effective Oct. 13 to pursue another opportunity.

Bausch Health shares fall after CFO resignation

Canopy Growth

Cronos Group

GrowGeneration Corp

Green Thumb Industries Inc.

Jazz Pharmaceuticals

Scotts Miracle-Gro

There's a reason people are looking for cannabis stocks to buy now. It is increasingly likely that marijuana will be rescheduled from a Schedule I controlled substance to a Schedule III controlled substance.

7 Cannabis Stocks to Buy BEFORE the Marijuana Rescheduling Boom

Bausch Health finance chief Tom Vadaketh will resign effective Oct. 13 to pursue another opportunity, the Canadian pharmaceutical company said in a regulatory filing Monday.

Bausch Health CFO Tom Vadaketh to resign effective Oct. 13

LAVAL, QC / ACCESSWIRE / September 18, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) ("BHC" or the "Company") today announced that Tom Vadaketh, Executive Vice President, Chief Financial Officer, has resigned from his role to pursue another opportunity, and will be leaving the Company effective October 13, 2023. The Company thanks Mr.

Bausch Health Announces CFO Transition Plan

LOS ANGELES, CA / ACCESSWIRE / September 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bausch Health Companies Inc. ("Bausch" or "the Company") (NYSE:BHC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2020 and May 3, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

SEPTEMBER 25 DEADLINE: The Schall Law Firm Encourages Investors in Bausch Health Companies Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Sept. 18, 2023 /PRNewswire/ -- Attention Bausch Health Companies Inc. ("Bausch") (NYSE: BHC) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 6, 2020 and May 3, 2023.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Bausch Investors of a Lead Plaintiff Deadline of September 25, 2023

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Bausch + Lomb Escrow Corp. (“Escrow Issuer”), a wholly owned subsidiary of the company, has priced its previously announced offering of $1.4 billion aggregate principal amount of 8.375% senior secured notes due 2028 (“Notes”). The Notes will be sold to investors at a price of 100% of the principal amount th.

Bausch + Lomb Announces Pricing of Senior Secured Notes Offering

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Bausch Health Companies Inc. (“Bausch”) (NYSE: BHC). The action charges Bausch with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Bausch's materially misleading statements and omissions to t.

Final Deadline Approaching for Bausch Health Companies Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Bausch Health Companies Inc. (BHC) Investors of September 25, 2023 Lead Plaintiff Deadline

LAVAL, QE / ACCESSWIRE / September 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce that following its approval by Health Canada the new treatment PrUCERIS® (budesonide) aerosol foam is now available across Canada to treat mild to moderate distal ulcerative colitis in adults. UCERIS is the only glucocorticosteroid rectal foam available in Canada indicated for the induction of remission in adult patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge.

New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. commercial launch of MIEBO (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation. “More and more Americans are suffering from dry eye disea.

Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States

LOS ANGELES, CA / ACCESSWIRE / September 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bausch Health Companies Inc. ("Bausch" or "the Company") (NYSE:BHC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2020 and May 3, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Bausch Health Companies Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Bausch Health Companies Inc. (NYSE:BHC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bausch-health-lawsuit-submission-form?prid=47654&wire=1 or contact Joseph E. Levi, Esq.

SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Bausch Health Companies Inc. (NYSE:BHC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bausch-health-lawsuit-submission-form?prid=47612&wire=1 or contact Joseph E. Levi, Esq.

SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

LAVAL, QC / ACCESSWIRE / September 11, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (the "Company") (NYSE/TSX:BHC), announced today that, in connection with the financing of its pending acquisition (the "Acquisition") of XIIDRA® and certain other ophthalmology assets, Bausch + Lomb Escrow Corp. (the "Escrow Issuer"), a wholly owned subsidiary of Bausch + Lomb, launched an offering of $1.4 billion aggregate principal amount of new senior secured notes due 2028 (the "Notes") and that Bausch + Lomb is seeking to enter into an incremental term loan facility ("Term Loan Facility"), which will be secured on a pari passu basis with Bausch + Lomb's existing term loan facility and will either be in the form of an incremental amendment to Bausch + Lomb's existing term loan facility or a separate credit agreement. Bausch + Lomb is expected to borrow $500 million of new term B loans (the "New Term B Loans") under the Term Loan Facility upon the closing of the Acquisition.

Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Bausch + Lomb Escrow Corp. (“Escrow Issuer”), a wholly owned subsidiary of the company, has launched an offering of $1.4 billion aggregate principal amount of new senior secured notes due 2028 (“Notes”) and that the company is seeking to enter into an incremental term loan facility, in each case in connecti.

Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

RADNOR, Pa. , Sept. 10, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Bausch Health Companies Inc. ("Bausch") (NYSE: BHC).

Bausch Health Companies Inc. (BHC) Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BHC Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf

LAVAL, QC / ACCESSWIRE / September 6, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has disclosed certain historical and pro forma financial information with respect to its previously announced proposed acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5% and certain other ophthalmology assets (the "Acquisition") on a Current Report on Form 8-K and on its SEDAR+ (www.sedarplus.ca) profile. In connection with the Acquisition, as previously disclosed, Bausch + Lomb anticipates incurring indebtedness (expected to be comprised principally of an incremental term loan and the issuance of senior secured notes), which is discussed in further detail in its Current Report on Form 8-K.

Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it has disclosed certain historical and pro forma financial information with respect to its proposed acquisition of XIIDRA (lifitegrast ophthalmic solution) 5% and certain other ophthalmology assets (“Acquisition”) on a Current Report on Form 8-K and on its SEDAR+ (www.sedarplus.ca) profile. In connection w.

News for Bausch Health Companies Inc Stock (BHC)